You are here
Efficacy and safety of crizotinib in patients with advanced c-MET-amplified non-small cell lung cancer (NSCLC).
J Clin Oncol 32:5s, 2014 (suppl; abstr 8001)
Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^).
Background: c-Met-amplified NSCLC defines a subset of NSCLC that may be sensitive to the small-molecule tyrosine kinase inhibitor crizotinib, approved multinationally for the treatment of advanced ALK-positive NSCLC. Efficacy and safety data are presented for crizotinib in patients with advanced c-Met-amplified NSCLC within 3 categories of amplification MET/CEP7 ratio ≥1.8-≤2.2 (Low), >2.2-<5 (Intermediate) and ≥5 (High). Methods: c-METamplification status was determined by FISH, with 10-12 patients to be enrolled into each amplification category. If 2 or more objective responses occur in a category, 19 additional patients are to be enrolled. This study is part of an ongoing phase 1 crizotinib study (NCT00585195). Patients received crizotinib 250 mg BID. Responses were assessed using RECIST v1.0. Results: At data cut-off, 16 patients were enrolled; 3 were subsequently determined not to have an amplification meeting MET/CEP7 criteria. 13 patients with c-MET-amplified NSCLC [Low (n=1), Intermediate (n=6) and High (n=6)] enrolled and received crizotinib, with 12 evaluable for response. Median age was 63 years (range 42-79), 92% of patients were ECOG 0 or 1 and 77% were ex-smokers. To date 4 PRs (33%; 95% CI: 10,65) have been observed (Low (n=0), Intermediate (n=1; 20%) and High (3; 50%). Median duration of response was 35 weeks [95% CI: 16,112]. Median treatment duration was 15.7 weeks (range 4 -188), and 6 patients were on treatment at the data cut-off; 5 patients have died (all disease-related). 75% of the 16 patients enrolled had treatment-related adverse events (AEs): most commonly diarrhea (50%), nausea (31%), vomiting (31%), peripheral edema (n=25%) and visual impairment (25%). Most AEs were grade 1 in severity. There were no treatment-related serious AEs or treatment-related permanent discontinuations. Accrual of patients with c-Met-amplified NSCLC is ongoing. Conclusions: Crizotinib appears to have antitumor activity in patients with c-Met-amplified NSCLC and a generally tolerable and manageable AE profile. These findings warrant further study of crizotinib in advanced c-MET-amplified NSCLC and ongoing exploration of the MET/CEP7 ratio associated with clinical benefit. Clinical trial information: NCT00585195.
Abstracts by D. Ross Camidge:
A phase 2 study of defactinib (VS-6063), a cancer stem cell inhibitor that acts through inhibition of focal adhesion kinase (FAK), in patients with KRAS-mutant non-small cell lung cancer.
A single arm, open-label, phase II study to assess the efficacy of lucitanib in patients with FGFR1-amplified squamous NSCLC (sqNSCLC).
Ceritinib in advanced anaplastic lymphoma kinase (ALK)-rearranged (ALK+) non-small cell lung cancer (NSCLC): Results of the ASCEND-1 trial.
Presentations by D. Ross Camidge:
Meeting: 2012 ASCO Annual Meeting
Session: Laboratory and Clinical Insights into Resistance to EGFR and ALK Inhibitors in Non-small Cell Lung Cancer (Education Session)
Native and rearranged ALK copy number and rearranged ALK cell count in NSCLC: Implications for ALK inhibitor therapy.Session: Lung Cancer - Non-small Cell Metastatic (Poster Discussion Session)
Meeting: 2011 ASCO Annual Meeting
Session: Lung Cancer - Metastatic/Non-small Cell (Oral Abstract Session)